Latest MR-proADM News

May 2018

publicationMR-proADM in Urinary Tract Infections

Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection

Objectives: Febrile urinary tract infections (fUTI) can often be treated safely with oral antimicrobials in an outpatient setting. However, a minority of patients develop complications that may progress into septic shock.

Read the full publication here >


May 2018

publicationMR-proADM in Sepsis

Identification of developing multiple organ failure in sepsis patients with low or moderate SOFA scores

An early identification of sepsis patients likely to progress towards multiple organ failure is crucial in order to initiate targeted therapeutic strategies to decrease mortality.

Read the full publication here >


April 2018

publicationMR-proADM in Sepsis and Cancer

Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin with Emphasis in Patients with Cancer

Sepsis and bloodstream infections remain a leading cause of death in immunocompromised patients with cancer. The management of these serious infections consist of empiric use of antimicrobial agents which are often overused.

Read the full publication here >


March 2018

publicationMR-proADM in Cardiology

Adrenomedullin: Continuing to explore cardioprotection

Adrenomedullin (AM), a peptide isolated from an extract of human pheochromocytoma, comprises 52 amino acids with an intramolecular disulfide bond and amidation at the carboxy-terminus.

Read the full publication here >


March 2018

publicationMR-proADM in community-acquired pneumonia (CAP)

Multidimensional Prognostic Index (MPI) and Proadrenomedullin plasma levels in predicting one-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP): a prospective study

Background: To evaluate the prognostic accuracy of proadrenomedullin (proADM) in comparison with and in addition to the Multidimensional Prognostic Index (MPI), a validated predictive tool for mortality derived from a comprehensive geriatric assessment (CGA) to predict one-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP).

Read the full publication here >


March 2018

publicationMR-proADM in Sepsis

The use of MR-proADM in assessing disease severity and treatment response in patients with sepsis and septic shock

In collaboration with the SepNet Critical Care Trials Group, a new analysis of 1089 patients with sepsis and septic shock across 33 German Intensive Care Units was recently published in Critical Care. MR-proADM could add significant value to identifying patients at risk of further disease progression, the earlier escalation of therapy in patients at risk of treatment failure, and the subsequent de-escalation of treatment and early discharge of low risk patients.

Read the News Press Release here >

Read the full publication here >


February 2018

publicationMR-proADM in the Laboratory

Plasma mid-regional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population

Robust reference intervals for MR-proADM concentrations in plasma were generated, with the recommended adoption of single reference intervals for the adult population as a whole.

Read the full publication here >


January 2018

publicationMR-proADM in Paediatrics

Reliability of Pro-adrenomedullin and Interleukin 1β in Predicting Severity of Community-Acquired Pneumonia in Pediatric Patients

Objectives: Community-acquired pneumonia (CAP) in children is one of the most important causes of mortality and morbidity in developing countries. Therefore, it is very important for clinicians to detect the presence and severity of pneumonia.

Read the full publication here >


January 2018

publicationMR-proADM in the Laboratory

Mid-regional proadrenomedullin (MR-proADM) reference values in serum

MR-proADM reference values in a healthy population using serum samples

Read the full publication here >


December 2017

publicationMR-proADM in Emergency Department Infections

Prognostic power of biomarkers for short-term mortality in the elderly patients seen in Emergency Departments due to infections.

Objectives: To analyse and compare 30-day mortality prognostic power of several biomarkers (C-reactive protein, procalcitonin, lactate, suPAR and pro-adremomedullin) in elderly patients seen in Emergency Departments (ED) due to infections.

Read the full publication here >


thermo scientific applied biosystems invitrogen fisher scientific unity lab service